NCT03847090: An overdue trial by Allena Pharmaceuticals
This trial is overdue. It was due to report 1 year, 10 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
Full entry on ClinicalTrials.gov | NCT03847090 |
---|---|
Title | Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2) |
Results Status | Overdue |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | Aug. 26, 2019 |
Completion date | May 19, 2022 |
Required reporting date | May 19, 2023, midnight |
Actual reporting date | None |
Date last checked at ClinicalTrials.gov | April 7, 2025 |
Days late | 689 |